Endocrinologist calls for earlier use of tirzepatide in T2DM patients

Watch this video for updated guidance on both new and established therapies for type 2 diabetes
3
16 February 2024
Save
ClosePlease login

In this clinical conversation, two Sydney-based doctors discuss the role of the new GIP/GLP-1RA class (tirzepatide) along with the more established treatment options such as insulin and the SGLT2i and GLP-1RA classes.

Watch endocrinologist Professor Ted Wu as he explains the expected responses to tirzepatide and how these compare with other antiglycaemic medications, particularly the GLP-1RA class, for HbA1c lowering and weight reduction.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .